報價延遲最少15分鐘:2025/02/23 03:54 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.21/2.01
|
|
企業價值
374.90M
|
| 資產負債 |
|
每股賬面淨值
0.61
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
--
|
|
每股收益
1.11
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 03:54 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. |